These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21064104)

  • 1. Identification of an aggressive prostate cancer predisposing variant at 11q13.
    Nurminen R; Wahlfors T; Tammela TL; Schleutker J
    Int J Cancer; 2011 Aug; 129(3):599-606. PubMed ID: 21064104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death.
    Nurminen R; Lehtonen R; Auvinen A; Tammela TL; Wahlfors T; Schleutker J
    Eur J Cancer; 2013 Oct; 49(15):3335-43. PubMed ID: 23830236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.
    Määttä KM; Nurminen R; Kankuri-Tammilehto M; Kallioniemi A; Laasanen SL; Schleutker J
    BMC Cancer; 2017 Jul; 17(1):496. PubMed ID: 28738860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.
    Benusiglio PR; Lesueur F; Luccarini C; McIntosh J; Luben RN; Smith P; Dunning A; Easton DF; Ponder BA; Pharoah PD
    BMC Cancer; 2005 Jul; 5():81. PubMed ID: 16029503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
    Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
    Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocalyxin variants and risk of prostate cancer and tumor aggressiveness.
    Casey G; Neville PJ; Liu X; Plummer SJ; Cicek MS; Krumroy LM; Curran AP; McGreevy MR; Catalona WJ; Klein EA; Witte JS
    Hum Mol Genet; 2006 Mar; 15(5):735-41. PubMed ID: 16434482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer.
    Wang L; McDonnell SK; Slusser JP; Hebbring SJ; Cunningham JM; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Cancer Res; 2007 Apr; 67(7):2944-50. PubMed ID: 17409399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
    Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of HPC2/ELAC2 polymorphisms with risk of prostate cancer in a population-based study.
    Stanford JL; Sabacan LP; Noonan EA; Iwasaki L; Shu J; Feng Z; Ostrander EA
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):876-81. PubMed ID: 14504198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.
    Severi G; Hayes VM; Padilla EJ; English DR; Southey MC; Sutherland RL; Hopper JL; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):610-2. PubMed ID: 17372260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer.
    Hebbring SJ; Fredriksson H; White KA; Maier C; Ewing C; McDonnell SK; Jacobsen SJ; Cerhan J; Schaid DJ; Ikonen T; Autio V; Tammela TL; Herkommer K; Paiss T; Vogel W; Gielzak M; Sauvageot J; Schleutker J; Cooney KA; Isaacs W; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):935-8. PubMed ID: 16702373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
    Baffoe-Bonnie AB; Smith JR; Stephan DA; Schleutker J; Carpten JD; Kainu T; Gillanders EM; Matikainen M; Teslovich TM; Tammela T; Sood R; Balshem AM; Scarborough SD; Xu J; Isaacs WB; Trent JM; Kallioniemi OP; Bailey-Wilson JE
    Hum Genet; 2005 Aug; 117(4):307-16. PubMed ID: 15906096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.
    Siltanen S; Syrjäkoski K; Fagerholm R; Ikonen T; Lipman P; Mallott J; Holli K; Tammela TL; Järvinen HJ; Mecklin JP; Aittomäki K; Blomqvist C; Bailey-Wilson JE; Nevanlinna H; Aaltonen LA; Schleutker J; Vahteristo P
    Eur J Hum Genet; 2008 Aug; 16(8):983-91. PubMed ID: 18337727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer.
    FitzGerald LM; Kwon EM; Conomos MP; Kolb S; Holt SK; Levine D; Feng Z; Ostrander EA; Stanford JL
    Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1196-203. PubMed ID: 21467234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer.
    Rökman A; Ikonen T; Mononen N; Autio V; Matikainen MP; Koivisto PA; Tammela TL; Kallioniemi OP; Schleutker J
    Cancer Res; 2001 Aug; 61(16):6038-41. PubMed ID: 11507049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
    Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
    Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
    Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.
    Bane AL; Mulligan AM; Pinnaduwage D; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2011 Jun; 127(3):831-9. PubMed ID: 21327470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the RNASEL gene in familial and sporadic prostate cancer.
    Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
    Am J Hum Genet; 2002 Jul; 71(1):116-23. PubMed ID: 12022038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.